Former Cutera executive chairman Daniel Plants and CEO David Mowry
April 12, 2023 11:11 AM EDTUpdated April 12, 09:09 PM
People

Amid dra­ma, Cutera toss­es out CEO and chair, ap­points re­place­ments

Paul Schloesser

Associate Editor

A medtech com­pa­ny has ter­mi­nat­ed two of its top ex­ec­u­tives “for cause,” ap­point­ing an in­ter­im CEO amidst dra­ma over com­pa­ny con­trol and a sub­stan­tial drop …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times